Vielen Dank für Ihre Anfrage.
Wir werden Sie innerhalb weniger Werktage kontaktieren.
(Geschäftseinheit Performance Materials, Sales Support Team)
Gebäude AIA Central, Ebene 39, Jl. Jend. Sudirman Kav. 48A, Jakarta Selatan, Indonesien
+62 21 2988 8557
Erfolg! Ihre Anfrage wurde an unser Vertriebsteam übermittelt.
Etwas ist schiefgelaufen! Bitte versuchen Sie es später erneut.
Wir haben 20 Elemente gefunden.
| Kontaktdaten des Antragstellers | |
| Vollständiger Name | |
| Unternehmen | |
| Position | |
| Telefonnummer | |
| Geschäftliche E-Mail-Adresse | |
| Lieferadresse | |
Thank you. Your request has been sent.
Refarmed Chemicals presents Alacepril, a premium-grade antihypertensive medication catering to the pharmaceutical industry's mandate for efficacy and safety. This ACE (Angiotensin-converting enzyme) inhibitor is an integral pharmaceutical compound used in the treatment of hypertension and to mitigate the risk of myocardial infarction in patients with left ventricular dysfunction. By inhibiting ACE, Alacepril decreases the production of angiotensin II, resulting in vasodilation, reduced vascular resistance, and consequently, lower blood pressure. Constructed as a white crystalline powder, Alacepril is noted for its commendable solubility in methanol and ethanol (95%), with moderate solubility in water, facilitating its versatile use in different medicinal formulations. With quality as its cornerstone, Alacepril assures a high purity level, with an assay (by titration) confirming a 98.0% to 101.0% concentration for optimal therapeutic benefit. Each impurity is rigorously controlled to ≤ 0.2% and total impurities to ≤ 0.5%, ensuring compliance with robust pharmaceutical standards. Alacepril is packaged with comprehensive documentation, including DMF and JDMF certifications, and is produced under EU GMP guidelines, reflecting an unwavering commitment to regulatory conformance and product integrity. Precautionary measures are accounted for, with guidelines established for patients with hepatic or renal impairment, and contraindications identified for populations at risk, including during pregnancy and when potential for specific drug interactions exists. With a rapid absorption and an onset of action within 1-2 hours, Alacepril maintains its therapeutic efficacy for approximately 24 hours, making it a convenient once-daily treatment. Renal excretion serves as its primary elimination pathway, underscoring the need for tailored dose adjustments in patients with renal impairment. Trust Alacepril from Refarmed Chemicals for effective blood pressure management, anchored by our dedication to safety, efficacy, and quality control. Experience the synergy of cutting-edge pharmaceutical science and comprehensive patient care with Alacepril—a flagship example of our mission to support health and well-being.
Products still subject to third-party patent protection might be available solely for R&D purposes.
Deferasirox, marketed under the brand Refarmed Chemicals, is a cornerstone in the treatment of chronic iron overload due to blood transfusions in conditions such as thalassemia and sickle cell disease. This condition, if not properly managed, can have severe consequences for organ function. Deferasirox is available in oral tablet form, with strengths of 250 mg, 500 mg, and 1000 mg, allowing for flexibility and precision in dosing to meet individual patient needs. Crafted as an iron chelator, Deferasirox plays a crucial role in binding excess iron within the body and facilitating its excretion through urine. This targeted mechanism asserts its importance in maintaining a healthy balance of iron and preventing the potential toxicity associated with overload. Patients are advised to take Deferasirox with or without food, adhering to a dosing schedule that is tailored to their specific iron levels and bodily response, underscoring the need for a personalized approach to treatment. Regarding its physical properties, Deferasirox appears as a white to pale yellowish crystalline powder, primarily soluble in DMF (Dimethylformamide) and slightly soluble in methanol. These characteristics are essential for ensuring its effectiveness and stability as a pharmaceutical agent. It is imperative that patients undergo regular blood tests and health monitoring for optimum results and to prevent adverse effects such as gastrointestinal distress, skin reactions, and potential liver or renal impairment. Additionally, care must be taken in cases of known hypersensitivity to Deferasirox or pre-existing severe renal or liver conditions. Our documentation and certifications like Good Manufacturing Practice (GMP) and the Drug Master File (DMF) guarantee the highest levels of quality and compliance with industry standards. It is our priority to ensure that this crucial pharmaceutical material is of the utmost purity and efficacy, as reflected in our stringent quality control parameters including the presence of residual solvents and related substances, all documented for your assurance. Please note that while Deferasirox is a vital medication for many patients, it requires diligent medical supervision. Always consult healthcare professionals for specific medical advice and treatment instructions tailored to individual health profiles.
Products still subject to third-party patent protection might be available solely for R&D purposes.
Bilastine is a white to off-white crystalline powder that is sparingly soluble in methylene chloride and practically insoluble in acetone. It has an assay range of 98.0% to 102.0%.
Products still subject to third-party patent protection might be available solely for R&D purposes.
Atorvastatin Calcium, provided by Refarmed Chemicals, is a potent pharmaceutical ingredient used by healthcare professionals in the management and prevention of several cardiovascular-related conditions. As an integral part of the statin class of medications, Atorvastatin Calcium serves a critical role in reducing cholesterol levels, specifically low-density lipoprotein (LDL) cholesterol, apolipoprotein B, and total cholesterol. It is also effective in lowering triglyceride levels and is indicated for the prevention of cardiovascular events such as ischemic strokes and transient ischemic attacks, particularly in patients who are at high risk of these events. This product is especially valuable for the treatment of familial heterozygous and homozygous hypercholesterolemia. However, it is contraindicated in individuals with known hypersensitivity to the active ingredient, those suffering from active liver disease, and should not be used during pregnancy and breastfeeding due to potential risks. Formulated as a white or almost white yellowish crystalline powder, Atorvastatin Calcium comes with comprehensive documentation and certifications, such as the Certificate of Suitability (CEP) and Good Manufacturing Practice (GMP) standards, ensuring its quality and safety. The material's purity is rigorously controlled, with an assay requirement of 98.0% to 102.0%, minimal water content, and strict limits on enantiomer impurities as well as residual solvents such as Methanol and Methyl tert-butyl ether, as specified in the provided image of its typical properties. Patients prescribed Atorvastatin Calcium should be under close medical supervision to monitor liver function and signs of muscle damage, a potential adverse effect. Muscle pain, diarrhea, nausea, headache, and flatulence are among the commonly reported side effects. Moreover, Atorvastatin Calcium can interact with several other medications, necessitating careful review by healthcare professionals when determining a patient's regimen. Refarmed Chemicals' rigorous adherence to quality and patient safety, as exemplified by their Atorvastatin Calcium product, fulfills the expectation of effectiveness and reliability desired by healthcare providers and wholesalers looking to distribute a product that can make a significant impact on public health.
Products still subject to third-party patent protection might be available solely for R&D purposes.